Thursday, Vertex Pharmaceuticals Incorporated (NASDAQ:VTRX) reported second-quarter revenues of $2.65 billion, almost in line with the consensus of estimate of $2.66 billion. Vertex Pharmaceuticals reported an adjusted EPS loss of $(12.83), compared to $3.89 a year ago, missing the consensus of $4.14. Product revenue increased by 6%, primarily driven by the continued strong performance of Trikafta/Kaftrio, including in younger age groups. In its earnings release, the company said that, based on Phase 1 biomarker analyses, it has determined that VX-634 and VX-668, two investigational small-molecule AAT correctors, would not deliver transformative efficacy for people with AATD. As such, Vertex has discontinued the development of both molecules. Guidance: Vertex raised its 2024 product revenue guidance from $10.55 billion-$10.75 billion to $10.65 billion-$10.85 billion. Vertex’s product revenue guidance includes ...